What's new in antiplatelet and anticoagulant therapy recommendations for unstable angina/non-ST-elevation myocardial infarction: 2012 focused update from the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Clinical Cardiology

Volumn 35, Issue 11, 2012, Pages 669-672

  Wenger, Nanette K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL PRACTICE; FOOD AND DRUG ADMINISTRATION; HEART DEATH; HUMAN; LOADING DRUG DOSE; MEDICAL SOCIETY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REVIEW; THROMBOCYTE FUNCTION; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

ADENOSINE; ADMINISTRATION, ORAL; ANGINA, UNSTABLE; ANTICOAGULANTS; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84869498379     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22065     Document Type: Review

References (10)

1. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA Focused Update on the Guidelines for the Management of Patients with Unstable Angina/Non-ST- Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012; 126: 875-910.
2. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015. (Pubitemid 350106708)
3. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.
4. Mahaffey KW, Wojdyla DM, Caroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011; 124: 544-554.
5. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502. (Pubitemid 32758501)
6. Eli Lilly and Co. Prasugrel label. 2009. US Food and Drug Administration Web site. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm171497. htm. Accessed May 2, 2012.
7. AstraZeneca. Brilinta REMS Document. NDA 22-433. 2011. US Food and Drug Administration Web site. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm263964.htm. Accessed May 2, 2012.
8. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). 2009. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugbreakSafetyInformationforHeathcareProfessionals/ucm079520.-htm. Accessed April 6, 2009.
9. Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members;, Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010; 122: 537-557.
10. Abraham NS., Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2010; 122: 2619-2633.